Detalles de la búsqueda
1.
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
J Eur Acad Dermatol Venereol
; 35(4): 938-947, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33068444
2.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
J Eur Acad Dermatol Venereol
; 35(1): 135-142, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32365251
3.
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
J Eur Acad Dermatol Venereol
; 32(9): 1507-1514, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29444376
4.
Short stature in retinoblastoma survivors: a cross-sectional study of 138 patients.
Clin Transl Oncol
; 18(4): 381-4, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26286069
5.
Short stature in retinoblastoma survivors: a cross-sectional study of 138 patients
Clin. transl. oncol. (Print)
; 18(4): 381-384, abr. 2016. tab, graf
Artículo
en Inglés
| IBECS (España) | ID: ibc-150452
Resultados
1 -
5
de 5
1
Próxima >
>>